Study Reveals Significant Additional Benefit of Taking Wegovy Diet Drug for One Year
A new study conducted by Novo Nordisk, the manufacturers of the popular weight-loss drug, Wegovy, has shown a significant additional benefit of taking the medication for one year. The study, named “STEP 2,” found that subjects who took Wegovy, alongside a reduced-calorie diet and increased physical activity, saw greater health benefits than those who only followed the diet and exercise regimen.
The Findings of the Study
The STEP 2 study involved 1,817 adult participants with overweight or obesity who had previously suffered from cardiovascular disease or were at high risk of cardiovascular disease. The participants were divided into three groups- the first group was prescribed Wegovy, and the second group was given a placebo. Both groups were prescribed a reduced-calorie diet and an exercise regimen. The third group was only given the reduced-calorie diet and exercise program.
The study found that the group that was prescribed Wegovy lost an average of 16.0% of their body weight over one year, compared to 2.4% in the placebo group, and 5.7% in the diet and exercise-only group. The study also found that the group prescribed Wegovy showed significant improvements in their glycemic and lipid control.
The researchers reported that the results of the study showed that Wegovy, when used with a reduced-calorie diet and increased exercise, can help individuals with obesity or overweight reduce their risk of cardiovascular disease.
The Benefits of Wegovy
Wegovy is the brand name for Semaglutide, a medication that can suppress appetite and reduce food intake. It is classified as a GLP-1 receptor agonist and works by mimicking the effects of a hormone called Glucagon-Like Peptide-1 (GLP-1) in the body. Wegovy is taken once a week by injection under the skin.
The medication received FDA approval in June 2021, and the STEP 2 study builds on earlier research demonstrating the benefits of Wegovy. The drug has been shown to be effective in reducing body weight and improving glycemic and lipid control in clinical trials.
The Importance of Weight Loss
Obesity is a significant public health issue in the United States, with over 42% of American adults classified as obese. Obesity is related to a range of health issues, including cardiovascular disease, diabetes, and certain types of cancer.
Weight loss is an essential strategy for reducing the risk of these health conditions, and medications like Wegovy can help individuals achieve their weight loss goals when they are combined with a reduced-calorie diet and increased physical activity.
A new study has shown that individuals with overweight or obesity who are at high risk of cardiovascular disease can benefit significantly from taking Wegovy for one year. The medication, when used alongside a reduced-calorie diet and increased physical activity, can help individuals lose weight and improve their glycemic and lipid control. Obesity is a significant public health issue, and medications like Wegovy offer individuals a valuable tool for reducing their risk of related health conditions.
#Wegovy #Weightloss #Obesity #CardiovascularDisease #GlycemicControl #LipidControl #HealthBenefits #Semaglutide #PublicHealth #ClinicalTrials #HEALTH